GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » CanSino Biologics Inc (HKSE:06185) » Definitions » Other Long-Term Liabilities

CanSino Biologics (HKSE:06185) Other Long-Term Liabilities : HK$213.7 Mil (As of Mar. 2024)


View and export this data going back to 2019. Start your Free Trial

What is CanSino Biologics Other Long-Term Liabilities?

CanSino Biologics's other long-term liabilities for the quarter that ended in Mar. 2024 was HK$213.7 Mil.

CanSino Biologics's quarterly other long-term liabilities declined from Sep. 2023 (HK$239.8 Mil) to Dec. 2023 (HK$217.3 Mil) and declined from Dec. 2023 (HK$217.3 Mil) to Mar. 2024 (HK$213.7 Mil).

CanSino Biologics's annual other long-term liabilities declined from Dec. 2021 (HK$230.8 Mil) to Dec. 2022 (HK$228.9 Mil) and declined from Dec. 2022 (HK$228.9 Mil) to Dec. 2023 (HK$217.3 Mil).


CanSino Biologics Other Long-Term Liabilities Historical Data

The historical data trend for CanSino Biologics's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CanSino Biologics Other Long-Term Liabilities Chart

CanSino Biologics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Other Long-Term Liabilities
Get a 7-Day Free Trial - - - - -

CanSino Biologics Quarterly Data
Dec16 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

CanSino Biologics Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.


CanSino Biologics Other Long-Term Liabilities Related Terms

Thank you for viewing the detailed overview of CanSino Biologics's Other Long-Term Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.


CanSino Biologics (HKSE:06185) Business Description

Traded in Other Exchanges
Address
185 South Avenue, 401-420, 4th Floor, Biomedical Park, TEDA West District, Tianjin, CHN
CanSino Biologics Inc is a China-based company engaged in the research and development, manufacturing and commercialization of vaccine products for human use. These include products such as pneumococcal polysaccharide and conjugate vaccines as well as a DTcP-based combo and other items. At the same time, the group is also dedicated to the development of new vaccine-like recombinant adenovirus vector-based tuberculosis vaccines and a recombinant protein-based pneumococcal vaccine. Geographically, the activities are carried out through China.
Executives
The Capital Group Companies, Inc. 2201 Interest of corporation controlled by you
Jpmorgan Chase & Co.
Citigroup Inc.
The Goldman Sachs Group, Inc. 2201 Interest of corporation controlled by you
Blackrock, Inc. 2201 Interest of corporation controlled by you
Mao Helen Huihua 2201 Interest of corporation controlled by you
Qiming Corporate Gp Iv, Ltd. 2201 Interest of corporation controlled by you
Qiming Gp Iv, L.p. 2201 Interest of corporation controlled by you
Qiming Venture Partners Iv, L.p. 2201 Interest of corporation controlled by you
Qm29 Limited 2101 Beneficial owner
Qiu Dongxu 2501 Other
Yu Xuefeng 2501 Other
Zhu Tao
Chao Shou Bai 2202 Interest of your spouse
Orbimed Capital Llc 2102 Investment manager

CanSino Biologics (HKSE:06185) Headlines

No Headlines